Mei Dong

Public Health Ontario

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Qing‐Wen Shi

Nanjing Boiler and Pressure Vessel Inspection Institute

Hiromasa Kiyota

Okayama University

Yu‐Cheng Gu

Syngenta (United Kingdom)

Françoise Sauriol

Queen's University

Bin Cong

Hebei Medical University

Zhi‐Yu Ni

Affiliated Hospital of Hebei University

Changhong Huo

Hebei Medical University

Chang‐Hong Huo

Hebei Medical University

Manli Zhang

First Hospital of Jilin University

Katherine Crosby

Cell Signaling Technology (United States)

Cooperative Institutions

Hebei Medical University

105

Chinese Academy of Medical Sciences & Peking Union Medical College

University of Toronto

Chinese Academy of Sciences

Shanghai Jiao Tong University

Sun Yat-sen University

Central South University

University of Chinese Academy of Sciences

Zhejiang University

Peking University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

New England Journal of Medicine (2010)

Giuseppe Saglio Dong‐Wook Kim Surapol Issaragrisil P. Le Coutre Gabriel Étienne

Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase.In this phase 3, randomized, open-label, multicenter study, we assigned 846 patients with chronic-phase Philadelphia chromosome-positive CML in a 1:1:1 ratio to receive nilotinib (at a dose of either 300 mg or 400 mg twice daily) or imatinib (at a dose of 400 mg once daily). The primary end point was the rate of major molecular response at 12 months.At 12 months, the rates of major molecular response for nilotinib (44% for the 300-mg dose and 43% for the 400-mg dose) were nearly twice that for imatinib (22%) (P<0.001 for both comparisons). The rates of complete cytogenetic response by 12 months were significantly higher for nilotinib (80% for the 300-mg dose and 78% for the 400-mg dose) than for imatinib (65%) (P<0.001 for both comparisons). Patients receiving either the 300-mg dose or the 400-mg dose of nilotinib twice daily had a significant improvement in the time to progression to the accelerated phase or blast crisis, as compared with those receiving imatinib (P=0.01 and P=0.004, respectively). No patient with progression to the accelerated phase or blast crisis had a major molecular response. Gastrointestinal and fluid-retention events were more frequent among patients receiving imatinib, whereas dermatologic events and headache were more frequent in those receiving nilotinib. Discontinuations due to aminotransferase and bilirubin elevations were low in all three study groups.Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive CML. (ClinicalTrials.gov number, NCT00471497.)

Philadelphia chromosome

Imatinib Mesylate

Clinical endpoint

Chronic myelogenous leukemia

10.1056/nejmoa0912614

Cite

Citations (1,615)

Xylomexicanins A and B, New Δ^14,15-Mexicanolides from Seeds of the Chinese Mangrove Xylocarpus granatum

Zeitschrift für Naturforschung C (2009)

Li‐Ru Shen Mei Dong Bao‐Wei Yin Dong Guo Manli Zhang

Two new mexicanolide-type limonoids, named xylomexicanin A (1) and xylomexicanin B (2), were isolated from seeds of the Chinese mangrove Xylocarpus granatum. Their structures were elucidated on the basis of spectroscopic methods. Compound 1 exhibited antiproliferative activity against human breast carcinoma cells (KT), while 2 did not show inhibitory effects on eleven human tumour cell lines tested.

10.1515/znc-2009-1-207

Cite

Citations (30)

Modified FOLFOX6 as the first-line chemotherapy for metastatic duodenal carcinoma.

Journal of Clinical Oncology (2011)

Mei Dong X. Wan X. Li Xixi Wu Qin Lin

e14512

10.1200/jco.2011.29.15_suppl.e14512

Cite

Citations (0)

(10E,12Z,15Z)-9-Hydroxy-10,12,15-octadecatrienoic Acid Methyl Ester as an Anti-inflammatory Compound fromEhretia dicksonii

Bioscience Biotechnology and Biochemistry (2000)

Mei Dong Yukiko Oda Mitsuru Hirota

The methanol extract of Ehretia dicksonii provided (10E, 12Z, 15Z)-9-hydroxy-10,12,15-octadecatrienoic acid methyl ester (1) which was isolated as an anti-inflammatory compound. Compound 1 suppressed 12-Otetradecanoyl-phorbol-13-acetate (TPA)-induced inflammation on mouse ears at a dose of 500 microg (the inhibitory effect (IE) was 43%). Linolenic acid methyl ester did not inhibit this inflammation at the same dose. However, the related compounds of 1, (9Z,11E)-13hydroxy-9,11-octadecadienoic acid (5) and (9Z,llE)13-oxo-9,11-octadecadienoic acid (6), showed potent activity (IE500 microg of 63% and 79%, respectively). Compounds 1, 4 ((9Z, 12Z, 14E)-16-hydroxy-9,12,14-octadecatrienoic acid), 5 and 6 also showed inhibitory activity toward soybean lipoxygenase at a concentration of 10 microg/ml.

Phorbol

Propanoic acid

10.1271/bbb.64.882

Cite

Citations (43)

A new alkaloid taxane composed of two N-formyl rotamers from the rooted cuttings of Taxus canadensis

Chemistry of Natural Compounds (2013)

Hong-Zhen Zhang Yu‐Fang Wang Man‐Li Zhang Mei Dong Chang‐Hong Huo

Conformational isomerism

Taxane

10.1007/s10600-013-0458-7

Cite

Citations (6)

Efficacy and safety evaluation of albumin-bound paclitaxel chemotherapy in East Asian patients with gynecological tumors based on the degree of paclitaxel binding to patient plasma

Anti-Cancer Drugs (2022)

Jiahui Liu Shuo Zhang Fang Yang Yichuang Yin Jiuhang Yu

Nab-PTX is a special dosage form of antitumor drug that is different from other injections. In order to explore the efficacy and safety of albumin-bound paclitaxel, we developed an analytical method with UPLC-MS/MS to quantify the total and free paclitaxel in plasma, and prospectively evaluate the impact of unbound fraction fu (%) on the prognosis and adverse reactions of patients with gynecological tumors. From 2020.10 to 2021.10, a total of 116 patients with gynecological tumors were included, application of albumin-bound paclitaxel combined with platinum chemotherapy drugs, the blood collection time is 18–30 h after nab-PTX intravenous infusion. The collection time and the start (end) time of intravenous drip are recorded correctly, and a high-precision and sensitive UPLC-MS/MS method for the simultaneous determination of total and free paclitaxel was established. With fu (%) = Cunbound/Ctotal as the evaluation index, the concentration of total paclitaxel and free paclitaxel were determined by UPLC-MS/MS. The value of fu (%) was closely related to clinical adverse reactions, neutropenia, thrombocytopenia, leukopenia and bone marrow suppression. Neurotoxicity was statistically remarkable ( P up0.001), and fu (%) has a significant correlation with clinical efficacy ( P up0.001). We have developed a highly precise, highly sensitive and specific UPLC-MS/MS method for the simultaneous determination of binding and free albumin-bound paclitaxel concentrations in patients’ serum. In addition, we found that fu (%) could be used as the detection index. The higher the fu (%) was, the more taxol could be free, the more adverse reactions related to toxic events occurred in patients.

Leukopenia

10.1097/cad.0000000000001459

Cite

Citations (1)

A new taxane from Taxus canadensis needles

Chemistry of Natural Compounds (2012)

Manli Zhang Zhi‐Yu Ni Yufang Wang Mei Dong Ligeng Li

Taxane

10.1007/s10600-012-0102-y

Cite

Citations (5)

Millifolide A, a dimeric ether of degraded sesquiterpene lactones, inhibited the proliferation of human lung cancer cell line A549

Natural Product Research (2021)

Pan-Pan Yu Feng Yu Wen-Zhe Li Si-Ming Wang Chuan Wang

The inhibitory effect of three degraded sesquiterpene lactones, iso-seco-tanapartholide, arteludooicinolide A and millifolide A isolated from Achillea millefolium L., on anti-human lung cancer cells was examined using MTT and reporter gene assays. Millifolide A has significant inhibitory effects on the proliferation of human lung cancer cells probably through inducing cell apoptosis.

Achillea millefolium

Sesquiterpene lactone

MTT assay

Human lung

10.1080/14786419.2021.1922906

Cite

Citations (1)

Supplementary Figures 1-2 from Loss of Betaglycan Expression in Ovarian Cancer: Role in Motility and Invasion

Nadine Hempel Tam How Mei Dong Susan K. Murphy Timothy A. Fields

Supplementary Figures 1-2 from Loss of Betaglycan Expression in Ovarian Cancer: Role in Motility and Invasion

10.1158/0008-5472.22367774.v1

Cite

Citations (0)

Antitumour Activities of Sesquiterpene Lactones from Inula helenium and Inula japonica

Zeitschrift für Naturforschung C (2012)

Yong Li Zhi‐Yu Ni Meng-Chu Zhu Mei Dong Si-Ming Wang

3 Eight sesquiterpene lactones were isolated from the roots of Inula helenium and fl owers of I. japonica. Among them, isoalantolactone () and santamarine ( 6 ) exhibited significant growth inhibitory activities against gynecologic cancer cell lines, while others weakly inhibited the growth of the cell lines (IC50 ≤ 100 μM). In addition, 3 significantly inhibited the tumour growth of S180 tumour-bearing mice. Compounds 3 and 6 were not toxic to human embryonic lung fibroblast cells in vitro. These results demonstrated that the antitumour activities are closely related to the structures of the compounds, that is, an α-exomethylene- γ-lactone ring is necessary for these activities.

Inula

Sesquiterpene lactone

10.1515/znc-2012-7-804

Cite

Citations (32)